Structure Therapeutics Eyes 2027 Data to Validate Weight-Loss Drug
GPCR's ACCG-2671 cut body weight 3.3% in a single dose, but repeat-dosing tolerability remains the key question.
Structure Therapeutics disclosed Tuesday that its experimental obesity drug ACCG-2671 achieved a mean 3.3% body-weight reduction from a single dose in an ongoing Phase 1/2a clinical trial, raising early hopes for a new entrant in the crowded GLP-1 weight-loss market. The San Francisco-based biotech, trading under the ticker GPCR, now faces the pivotal question that every single-dose signal must answer: can the effect hold — and can patients tolerate it — over weeks of continuous treatment?
To find out, the company has launched an 84-day study evaluating both daily and weekly dosing regimens of ACCG-2671. Investors and analysts will have to wait for results, with top-line data from that extended trial not expected until the first half of 2027. The timeline means Structure Therapeutics carries meaningful clinical and financing risk over the next two years as it burns cash ahead of a readout that could define the drug's future.
Read more Leopold Aschenbrenner's Situational Awareness Fund Buys Options in AMD, Coreweave →
The central scientific challenge is gastrointestinal tolerability. Even at lower dose levels in the Phase 1/2a study, ACCG-2671 produced significant adverse GI events — a familiar hurdle for drugs that act on gut-related receptors. Managing that side-effect profile while preserving the weight-loss signal at repeat-dose levels is the make-or-break task for the compound. Rivals in the obesity space, including approved semaglutide products, have set a high bar on both efficacy and patient retention.
If the 84-day data confirm that weekly or daily dosing can replicate or exceed the initial 3.3% reduction without unacceptable side effects, ACCG-2671 could credibly advance toward larger, longer trials. A failure to maintain tolerability, however, would likely trigger a dose-optimization detour that pushes any pivotal program further into the future. The 2027 readout will therefore serve as a binary catalyst for Structure Therapeutics shareholders.
Continue reading at Yahoo Finance.
